Outlook Therapeutics Sets Path for Ophthalmic Treatment Breakthrough with Request for Marketing Authorization in the UK
Iselin, NJ-based biopharmaceutical company Outlook Therapeutics, Inc. (Nasdaq: OTLK) has set the bio-pharmaceutical sector abuzz with its latest move. The company, currently working on obtaining regulatory approval for the first-ever use of an ophthalmic formulation of bevacizumab for treating retinal diseases in the US and Europe, has recently announced the submission of its Marketing Authorization Application (MAA) to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).
This application, if granted, will provide the firm with the authority to market its breakthrough product, ONS-5010/LYTENAVA (bevacizumab gamma), intended to treat wet age-related macular degeneration (wet AMD). This eye condition is a leading cause of vision loss in people over the age of 50, causing blurred or reduced vision in the center of the visual field. This bold step of the company marks a significant milestone in its mission to transform vision care, offering new hope for millions affected by this vision problem worldwide.
Outlook Therapeutics, in a longstanding commitment to provide cost-effective ophthalmic therapeutics for retinal diseases, has been extensively working to use bevacizumab, traditionally a cancer drug, for ophthalmic purposes. Researchers believe that Bevacizumab, known for its anti-angiogenic properties, can help contain the formation of new blood vessels in the eye, a common occurrence in various eye diseases including wet AMD.
The submission of the MAA application is another step forward in the company’s strategy to secure regulatory acceptance for ONS-5010/LYTENAVA in major markets worldwide. Given the high incidence rate of wet AMD, approval of this drug could dramatically influence the landscape of ophthalmic care, providing an affordable and effective solution for an aging population globally.
The bio-pharmaceutical sector will surely be watching attentively to see how Outlook Therapeutics’ cutting-edge solution navigates the regulatory pathway in the UK and potentially changing the face of treatment for this common, yet devastating visual ailment.
Comments